Targeting Vascular INflammation in Patients With Community-Acquired Pneumonia
Key facts
- Who runs it
- Ottawa Heart Institute Research Corporation
- Where
- Canada1 site in 1 countryChoose a country to see its sites
- Trial code
- Status
- Recruiting
- Phase
- Phase 3
- People taking part
- 168 people, planned
- Started
- 8 Apr 2026
- Expected to end
- Jun 2027
- Type of study
- Interventional, 2 groupsOne group gets a placebo (a dummy treatment), for comparison.
- Treatments tested
- Icosapent Ethyl 1000 MG Oral Capsule [Vascepa]
- Placebo
- Record updated
- 11 May 2026
Who can take part
- Age
- 18 years and older
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 14 criteriaShow less
Who can take part
- Patients who have:
- Hospitalization with CAP (defined as pulmonary infiltration using chest imaging, in addition to other clinical symptoms including fever, cough, and sputum)
- age > 18 years
- given informed consent
Who cannot take part
- history of cancer within the last 3 years (other than a successfully treated cutaneous squamous cell or basal cell carcinoma or localized carcinoma in situ of the cervix)
- active inflammatory conditions (e.g. rheumatoid arthritis, chronic inflammatory bowel disease, SLE, systemic anti-inflammatory therapy (e.g. prednisone, methotrexate))
- Allergies to icosapent ethyl
- allergies to fish or shellfish
- unable to give informed consent; Exclusion for CTA portion of the protocol:; Patients with dye allergy will not undergo CTA but will have PET/CT
- glomerular filtration rate (GFR) <50 ml/min/1.72m2 (excluded from CTA portion)
- Patients who have:
- pregnancy (all women of child bearing potential will have a negative BHCG test
- breastfeeding
- Women of childbearing potential who refuse to use two forms of contraception (this includes at least one form of highly effective and one effective method of contraception) throughout the study OR men capable of fathering a child who refuse to use contraception
This trial is currently available in Canada.
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
The goal of this clinical trial is to learn if icosapent ethyl (Vascepa) works to lessen the amount of inflammation in adults diagnosed with Community-Acquired Pneumonia (CAP). The main question it aims to answer is:
Read full original descriptionShow less
What is the effect of taking Vascepa on inflammation in the arteries in patients with CAP? Researchers will compare the drug Vascepa to a placebo (a look-alike submstance that contains no drug) to see if Vascepa works to reduce inflammation in patients with CAP.
Participants wil:
* take Vacscepa or a placebo twice a day for 6 months * Visit the clinic 3 times (baseline, 30 days, and 6 months) for checkups and tests
The 2 groups in the trial
- TreatmentTreatment being tested
Participants randomized to this arm will receive Vascepa for 6 months.
Treatment: Icosapent Ethyl 1000 MG Oral Capsule [Vascepa]
- PlaceboPlacebo, for comparison
Participants randomized to this arm will receive placebo for 6 months.
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Targeting Vascular INflammation in Patients With Community-Acquired Pneumonia (TIN_CAP): a Multi-centre, Prospective, Randomized Control Trial
- Publications
- Record updated
- 11 May 2026